DS Biopharma (DS) Announces that Recruitment has Begun in Two Separate Phase 2b Atopic Dermatitis Studies with Lead Compound DS107 as well as the Successful Completion of a Phase 1 trial for Follow on Compound DS109
Dublin (ots/PRNewswire) - DS Biopharma (DS), a privately held, clinical stage, pharmaceutical drug discovery and development company, today announced that recruitment has begun in two separate Phase 2b atopic dermatitis (AD) studies with its lead compound DS107. An Oral DS107 Phase 2b study (called 'ADvance') in 300 ...
mehr